SCHEMBL2935635

SCHEMBL2935635

Cc1cc2c(C)c(N)ccc2[nH]1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 2/20 0.47
CYP2A6 P11509 1/20 0.47
ALDH1A1 P00352 7/20 0.44
KDM4E B2RXH2 6/20 0.44
GAA P10253 5/20 0.44
MAPT P10636 4/20 0.44
RXFP1 Q9HBX9 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
VCP P55072 1/20 0.43
NQO2 P16083 1/20 0.42
HPGD P15428 6/20 0.42
CYP1A2 P05177 2/20 0.42
LMNA P02545 2/20 0.42
NFE2L2 Q16236 1/20 0.42
PARP1 P09874 1/20 0.42
GLA P06280 2/20 0.41
HSD17B10 Q99714 2/20 0.41
HTT P42858 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3524315 0.80 KEAP1 (0.47) KEAP1CYP2A6ALDH1A1KDM4EGAA
SCHEMBL22889556 0.80 GAA (0.47) KEAP1CYP2A6ALDH1A1KDM4EGAA
SCHEMBL4424885 0.79 NQO2 (0.57) KEAP1CYP2A6ALDH1A1KDM4EGAA
SCHEMBL1353956 0.75 PARP1 (0.59) KEAP1CYP2A6ALDH1A1KDM4EGAA
SCHEMBL20259660 0.75 HPGD (0.50) KEAP1CYP2A6ALDH1A1KDM4EGAA
SCHEMBL1406090 0.75 KEAP1 (0.50) KEAP1CYP2A6ALDH1A1KDM4EGAA
SCHEMBL15373471 0.75 NR1I2 (0.51) KEAP1ALDH1A1KDM4EGAAMAPT
SCHEMBL16892344 0.75 NQO2 (0.53) KEAP1CYP2A6ALDH1A1KDM4EGAA
SCHEMBL27896910 0.74 NGFR (0.54) ALDH1A1KDM4EGAAMAPTHPGD
SCHEMBL16065331 0.72 ALDH1A1 (0.49) KEAP1ALDH1A1KDM4EGAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3763710-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF Kala Pharmaceuticals, Inc. (US) 2021-01-13 EP disclosed
EP-2029543-B1 SUBSTITUTED 3-CYANOPYRIDINES AS PROTEIN KINASE INHIBITORS WYETH LLC (US) 2015-11-18 EP disclosed
CN-101466678-B Substituted 3-cyanopyridines as protein kinase inhibitors WYETH CORP 2012-12-26 CN disclosed
EP-2229377-A1 5-ALKYL/ALKENYL-3-CYANOPYRIDINES AS KINASE INHIBITORS Wyeth LLC (US) 2010-09-22 EP disclosed
US-7781591-B2 Substituted 3-cyanopyridines as protein kinase inhibitors WYETH LLC (US) 2010-08-24 US disclosed
CN-101466678-A Substituted 3-cyanopyridines as protein kinase inhibitors WYETH CORP (US) 2009-06-24 CN disclosed
WO-2009076602-A1 5-ALKYL/ALKENYL-3-CYANOPYRIDINES AS KINASE INHIBITORS WYETH (US) 2009-06-18 WO disclosed
EP-2029543-A2 SUBSTITUTED 3-CYANOPYRIDINES AS PROTEIN KINASE INHIBITORS Wyeth (US) 2009-03-04 EP disclosed
WO-2007146376-A2 SUBSTITUTED 3-CYANOPYRIDINES AS PROTEIN KINASE INHIBITORS WYETH (US) 2007-12-21 WO disclosed
US-20070287708-A1 Substituted 3-cyanopyridines as protein kinase inhibitors WYETH LLC 2007-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287708-A1 Substituted 3-cyanopyridines as protein kinase inhibitors CNKSR1, MAP3K1, MAP3K7 KEAP1 1364/4885CYP2A6 2820/4885ALDH1A1 2828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.